
June 23 (Reuters) - Fractyl Health Inc GUTS.O:
FRACTYL HEALTH REPORTS POSITIVE 3-MONTH REVEAL-1 COHORT DATA SHOWING REVITA® SUSTAINED WEIGHT LOSS AFTER GLP-1 DISCONTINUATION, SUPPORTING ITS POTENTIAL AS A FIRST-IN-CLASS WEIGHT MAINTENANCE THERAPY
FRACTYL HEALTH INC - 12 OF 13 PARTICIPANTS MAINTAINED OR LOST WEIGHT AT 3 MONTHS
FRACTYL HEALTH INC - REVITA SHOWS EXCELLENT TOLERABILITY PROFILE COMPARED TO GLP-1 DRUGS
FRACTYL HEALTH INC - RANDOMIZED MIDPOINT COHORT DATA EXPECTED IN Q3 2025
FRACTYL HEALTH INC - MEDIAN WEIGHT REMAINED STABLE THROUGH 3 MONTHS